+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice



Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice



Journal of Antimicrobial ChemoTherapy 52(3): 419-427



To study the toxicity and activity of two new amphotericin B formulations: poly(epsilon-caprolactone) nanospheres coated with poloxamer 188 (AmB-NP) and mixed micelles with the same surfactant (AmB-MM). The toxicity of these formulations was evaluated in erythrocytes, J774.2 macrophages and LLCPK1 renal cells, as well as in mice. Activity was determined in clinical isolates and in neutropenic mice. Mice were made neutropenic with 5-fluorouracil, infected with Candida albicans and treated with the antifungal formulations for three consecutive days. AmB association in cells and accumulation in kidneys and liver of animals was quantified by HPLC. Both formulations decreased between 8- and 10-fold the MIC of the polyene against clinical isolates of C. albicans. However, their activity was lower than or equal to that of AmB-deoxycholate when it was assessed against C. albicans-infected macrophages. When given as a single intravenous dose in mice, AmB-MM and AmB-NP had an LD50 of 9.8 and 18.6 mg/kg, respectively, compared with 4 mg/kg for AmB-deoxycholate. Comparison of residual infection burdens in the liver and kidneys showed that AmB-deoxycholate (0.5 mg/kg) was more effective and faster in eradicating yeast cells than polymeric formulations. This fact can be related to a lower AmB accumulation inside macrophages and in liver and kidneys (about 1.5 mg drug/g tissue) of mice, compared with those detected for AmB-deoxycholate (4 mg drug/g). Overall, the efficacy of these formulations at 2 mg/kg was equal to that of AmB-deoxycholate at 0.5 mg/kg. AmB-MM and AmB-NP decreased the in vivo antifungal activity of AmB, and higher concentrations were therefore necessary to obtain a similar therapeutic effect. However, these higher concentrations were achievable owing to the reduced toxicity of these formulations.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011165734

Download citation: RISBibTeXText

PMID: 12888593

DOI: 10.1093/jac/dkg351


Related references

Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrobial Agents and ChemoTherapy 39(9): 1954-1958, 1995

Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice. Antimicrobial Agents and ChemoTherapy 44(6): 1598-1603, 2000

Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis. Experimental Parasitology 169: 34-42, 2016

Therapeutic efficacy of a composition of amphotericin B and dialdehyde dextran in kidney damage in mice of various strains with systemic candidiasis. Bulletin of Experimental Biology and Medicine 146(6): 826-828, 2008

PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice. Journal of Clinical Microbiology 34(1): 25-28, 1996

Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans. European Journal of Pharmaceutical Sciences 22(5): 451-458, 2004

Toxicity and efficacy of low dose amphotericin b amp b for systemic neonatal candidiasis. Clinical Research 38(4): 926A, 1990

Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrobial Agents and ChemoTherapy 26(2): 170-173, 1984

Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrobial Agents and ChemoTherapy 31(12): 1897-1900, 1987

Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrobial Agents and ChemoTherapy 33(9): 1544-1548, 1989

Antifungal activity and renal toxicity of free and liposomal amphotericin B in diabetic rats with systemic candidiasis. Pharmaceutical Research (New York) 12(9 Suppl. ): S403, 1995

Treatment of systemic candidiasis in a neutropenic murine model using immunoglobulin G bearing liposomal amphotericin B. Mycopathologia 123(1): 9-17, 1993

Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine model. Journal of Medical and Veterinary Mycology 29(6): 419-421, 1991

A neutropenic murine model developed for treatment of systemic candidiasis using liposomal amphotericin b bearing antibodies. Abstracts of the General Meeting of the American Society for Microbiology 91: 408, 1991

Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice. Journal of Infectious Diseases 150(2): 278-283, 1984